

Date: 10.02.2020

To, The Secretary, The B.S.E Limited Floor 25, P.J. Towers, Dalal Street, Mumbai - 400 001

Sub: Submission of Un-Audited Standalone Financials Results of the Company and Limited Review Report as per Provisions of Regulation 30, 33 of SEBI (LODR) Regulations, 2015.

Please find enclosed here with the following Documents in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015:

- Financial Results: Un-Audited Standalone & Consolidated Financial Results of the company for the Third Quarter Ended 31st December, 2019.
- Limited Review Report: A Certified Copy of the Limited Review Report on Standalone Financials for the Third Quarter Ended 31st December, 2019 by the Auditors.

This is for your Information and Necessary Records.

Thanking you

For TRIMURTHLLIMITED

Arun Kunta Bhangadia

Managing Director DIN: 00021024

TRIMURTHI LIMITED

(Formerly known as Trimurth) Drugs & Pharmaceuticals Ltd.) 4-4-231/1/2/ABC. Inderbagh, Sultanbazar, Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370

Email: Info@trimurthidrugs.com Website: www.trimurthidrugs.com CIN No: L67120TG1994PLC018956



Date: 10/02/2020

To, The Secretary, The B.S.E Limited Floor 25, P.J. Towers, Dalal Street, Mumbai- 400 001

Sub: Outcome of the Board Meeting held on 10/02/2020 as per Regulation 30, 33 of SEBI (LODR) Regulations, 2015

Dear Sir/Madam,

The Board of Directors of the Company at its meeting held today, Monday, the 10th Day of February, 2020 at Registered Office, have approved and taken on record the following:

- 1. The Board has considered and approved the minutes of the previous board meeting.
- The Board has considered and approved the Unaudited Standalone & Consolidated Financial Results for the Third Quarter ended 31st December, 2019 along with Limited Review Report issued by the Statutory Auditors of the Company in compliance with Indian Accounting Standards (Ind-AS), SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013.

There being no other matter meeting of the Board of Directors concluded with the vote of thanks.

The Meeting of the Board of Directors of the company commenced at 03.30 P.M. and Concluded at 04:30 P.M.

Request you to take same on records.

Thanking you

For TRIMURTHI LIMITED

Arun Kuma Bhangadia Managing Director

DIN: 00021024

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.) 4-4-231/1/2/ABC, Inderbagh, Sultanbazar,

Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370

Email: into@trimurthidrugs.com Website: www.trimurthidrugs.com CIN No: L67120TG1994PLC018956

TRIMURTHI LIMITED

4-4-231/1/2/ABC, Inder Bagh, Sultan Bazar, Hyderabad - 500095. STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 2019



NINE MONTHS INCH A PRANCES QUARTER ENDED 31.12.2019 (31,03)2019 31.12.2018 (UNAUDITE (UNAUDITE 30.09.2019 31.12.2019 (AUDITED) PARTICULARS (UNAUDITED) (UNAUDITED) Di (UNAUDITED) Di 359.19 310.36 52.20 100 00 1. INCOME 13.23 INCOME FROM OPERATIONS 36.90 45.31 8.26 11.90 372.43 312.45 OTHER INCOME 56,57 89.10 23.00 30.24 TOTAL INCOME 277,05 250.31 2. EXPENSES 48.41 89.56 18.37 12.94 PURCHASES COST OF MATERIALS CONSUMED 0.03 (0.14)MANUFACTURING EXPENSES 8.57 (7.30) 1.52 3.91 3.00 WORK IN PROGRESS AND STOCK IN TRADE 1.00 0.90 0.30 0.60 32.72 24.65 0.95 21.40 RENT 7.35 8.57 EMPLOYEE BENEFITS EXPENSE 12.15 8.81 6.90 FINANCE COSTS 1.97 2.90 2.26 28.39 23.69 DEPRECIATION AND AMORTISATION EXPENSES 16.91 2.17 4.55 1.69 355.34 307.58 98.10 OTHER EXPENSES 98.18 34.36 31.67 TOTAL EXPENSES 3. PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE 19.08 (9.00) 4.88 0.35 (11.36 0.42 EXCEPTIONAL ITEMS (1-2) & EXCEPTIONAL ITEMS/ PRIOR PERIOD ITEMS 19.06 4.69 (9,00) 0.39 (11.36)PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE TAX ((1.42 (54.92) (9.44) 0.06 (4.74) (1.02) 0.00 6. TAX EXPENSES 4.49 0.70 0.70 (1.10) CURRENT TAX -TAX ADJUSTMENTS RELATING TO EARLIER YEARS (10.04) (10.14)0.06 5.44 0.08 0.01 -DEFERRED TAX (NET) 7. NET PROFIT/(LOSS) FROM ORDINARY ACTIVITIES AFTER (9.06) 14.31 25,00 5.13 (10.34) (1.43)8.PROFIT /(LOSS) FROM DISCONTINUED OPERATIONS 9. TAX EXPENSES FOR DISCONTINUED OPERATIONS 10.PROFIT /(LOSS) FROM DISCONTINUED OPERATIONS (AFTER TAX) (8-9) 25.00 14.31 (9.06)(10.34)5.13 (1.43)11.PROFIT/(LOSS) FOR THE PERIOD (7+10) 12.OTHER COMPREHENSIVE INCOME 1,086 (ii) INCOME TAX RELATING TO ITEM THAT THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS (6.20) (10.12)(2.30)(1,42) 0.67 9. (I) ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS (0.19) (ii) INCOME TAX RELATING TO ITEM THAT THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS 13. TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (11+12) (COMPRISING PROFIT (LOSS) AND OTHER 15.50 4.19 (10.49) 2.82 (9.67) (1.62)COMPREHENSIVE INCOMES 14.EARNINGS PER EQUITY SHARE (FOR CONTINUING 0.31 OPERATION): 0.78 0.06 (0.02) (0.13)0.31 (I) BASIC 0.38 (0.11)0.06 (0.13)(0.02) (ii) DILUTED 15 EARNINGS PER EQUITY SHARE (FOR DISCONTENUING OPERATION: (I) BASIC ii) DILUTED 16 EARNINGS PER EQUITY SHARE (FOR CONTINUING AND DISCONTINUING OPERATION) 0.18 0.06 48.138 (0.02) 0.31 (I) BASIC 10.09 (0.13 0.06 (0.02 00 DILUTED



TRIMURTHI LIMITED

Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.) 4-4-231/1/2/ABC, Inderbagh, Sultanbazor, Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370

Email: infa@trimurthidrugs.com Website: www.trimurthidrugs.com CIN No: L67120TG1994PLC018956

TRIMURTHI LIMITED SCHEDULE III OF THE COMPANIES ACT 2013 PART-II



		NINE MONTHS ENDED				
PARTICULARS	31.12.2019 (UNAUDITED)	30.69.2019 (UNAUDITED)		UNAUDITE D)	THE N	ROUP
PARTICULARS OF SHARE HOLDING				-	50 50 100	29,00,400
Public Share Holding	29,00,600	29.00,600	29.00,600	29,00,600	29,00,600 35,81%	35,81%
- Number of Shares	35.81%	35.18%	35.81%	35.81%	33.01%	-5021
the contract of abanelookding		7.00		-		
Penmoters and promount group triangularity				-	-	
Pledged / encumbered No of Equity Shares No of Equity Shares		-		-	6.1	-
- Percentage of Shares (of the shareholding of promoter and	-	-		7	-	
No of Equity Shares Percentage of Shares (of the shareholding of promoter and Percentage of Shares (of the total share capital of the company)	-		********	** PEC 1750	\$1,99,400	51,99,400
b. Non encumbured	51,99,400	51,99,400	51,99,400	51,99,400		51,99,400
				1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		
No of Equity Shares Processage of Shares (of the shareholding of promoter and Processage of Shares (of the total share capital of the company)	64.19%	64:19%	64.193	94.14		-

-	C.112001000	3 Months Ended (31/12/2019)
	Particulars	
	Investor Complaints	
	Pending at the beginning of the quarter	
_	Received during the quarter	
_	Disposed during the quarter	
_	Remaining amorived during the quarter	

TRIMURTHI LIMITED Segment Reporting

			William Street Street, Colonian Street,	YEAR ENDED			
	PARTICULARS	33,12.2019 (UNAUDITED)	QUARTER ENDER 30.09.2019 (UNAUDITED)	31.12.2018 (UNAUDITED)	33.12.2019	31.12.2018 (UNAUDITE D)	31.03.2019 (AUDITED)
-	Segment Revenue				4		140
	a. Pharma Business	1	8.21	14.13	31.89	44.94	57,64
	b. Financial Services	10.90	0.06	(0.23)	5.01	1.85	12.99
	c. Investments	1.10	14.73	3.56	52.20	20.83	30.51
	d. Trading in Shares	18.34	14.73	81.10		244.87	270.99
	e Foods		23.00	98,56	89.30	312.45	372.43
Fotal		30.24	23.00	100.00	+	-	74
PSS	Inter Segment Revenue		23.00	95.50	89.10	312.45	372.43
Net 5	ales/Income From Operations	30.24	25.00	39.54			
2	Segment Profits (Before tax & Interest From Each Segment)		- :				4
-	s. Phanna Business	10.90	15.05	11.85	31,89	36.66	45.45
	b. Figurcial Services	1.10		44400		1.85	12.99
	C Investments		1			9.16	13.97
_	d. Trading in Shanes	(13.32	100.11	(13.67		(42.82)	
	e. Foods	17.44	(11.00	74,000		4.88	19.08
Tota	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	(1.42	(11.ee	*			
Less			-	-	-		
	i. Interest	-	-	-	140		+
	ii. Other Un-allocable expenses not off		-		1.5		
	iii. Up-allocable Income	(1.4)		0.4	(9.00	4.88	19.08
	Total Profit Before Tax	(1.4)	- Creek	×			
3.	Capital Employed	29.9			29.50	0	
	A. Fharma Business	369.9		537.9	6 369.9		
	b. Financial Services	30.7	-				and the second s
	r. bayestments	460.9			0 460.9		
	d. Trading in Shares	300.0		The second secon	5 300.0		
	e foods	1,190.5	-	-		6 1,156.4	1,201.0
	Total	1,1790/3	4,174.0				

Notes

Previous period figures have been regrouped, wherever necessary, for the purpose of comparison. The financial results were reviewed by the Audit Committee and then approved at the meeting of the Board of Directors of the Company held on 10-02-2020

The above standalone financial results have been prepared in accordance with the recognition and measurement principles, laid down in the Ind. AS 34-Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules, issued there under and the other accounting principles, generally accepted in India.


Place: Hyderabad Date: 10-02-2020



TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Etd.) 4-4-231/1/2/ABC, inderbagh, Sultanbazar, Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370

Email: info@trimurthidrugs.com Website: www.trimurthidrugs.com CIN No: L67120TG1994PLC018956



Tel. : (91-40) 2332 6666, 2331 2554 2339 3967, 2332 1470

Fax : (91-40) 2339 2474 E-mail : pmurali.co@gmail.com


info@pmurali,com Website : www.pmurali.com


Limited Review Report- Standalone Financial Results

To The Board of Directors, Trimurthi Limited, Hyderabad,

Limited Review Report on unaudited standalone financial results for the Quarter and Nine Month ended 31th December 2019

- 1. We have reviewed the accompanying statement of unaudited standalone financial results of Trimurthi Limited ("the Company") for the quarter ended 31th December 2019 and year to date results for the period 1th April 2019 to 31th December 2019 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including relevant circulars issued by SEBI from time to time.
- 2. The preparation of "the Statement" in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India read with circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company in their meeting held on 10th February 2020. Our responsibility is to issue a report on the Statement based on our review.
- 3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.





: (91-40) 2332 6666, 2331 2554

2339 3967, 2332 1470

: (91-40) 2339 2474 Fax E-mail: pmurali.co@gmail.com

info@pmurali.com

Website: www.pmurali.com

 Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co. Chartered Accountants

FRN: 007257S

Partner

M.No. 024784

UDIN: 20024784AAAABX5709

Place: Hyderabad Date: 10-02-2020

TRIMURTHI LIMITED SCHEDULE III OF THE COMPANIES ACT 2013

CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE NINE MONTHS ENDED 31ST DECEMBER, 2019 PART-I



		QUARTER ENDED			NINE MON	YEAR ENDE	
	Particulars	31.12.2019 (UNAUDITED)	30.09.2019 (UNAUDITED)	31.12.2018 (UNAUDITED)	31.12.2019 (UNAUDITED)	31.12.2018 (UNAUDITED)	31.03.2018 (AUDITED)
I.	Income From Operations						
	Net Sales / Income from Operations	252.26	262.26	249.67	758.20	790.53	1,045.9
	Other Income	14.38	20.18	0.01	38.81	2.80	37.7
II.	Total Income	266.64	282.44	249.67	797.01	793.33	1,083.6
Ш.	Expenses	9		70000		-	*100010
977	a. Consumption of Raw Material	154.05	35.59	39.70	221.11	125.39	154.2
	b. Purchase of Traded Goods/Shares	119.11	154.42	153.91	411.44	447.57	594.2
	c. (Increase)/Decrease in stock in trade and work in Progress	3.30	(0.18)	(18.44)	(6.55)	(17.28)	1.9
	d. Manufacturing Expenses	(45.92)	64.39	39.01	57.70	117.00	153.8
	e. Employee benefits expense	24.97	26.24	29.82	73.45	75.67	98.6
	f. Rent	1.50	1.50	2.20	4.50	5.85	7.8
	g. Finance Cost	3.01	2.67	2.93	9.38	9.61	12.9
_	h. Depreciation	5.07	4.73	5.14	15.13	15.49	21.2
	i. Other Expenditure	11.50	10.78	10.02	36.86	40.75	51.1
	Total	276.60	300.13	264.28	823.02	820.05	1,096.05
v.	Profit/ (Loss) before Exceptional and Tax (II- III)	(9.95)	(17.69)	(14.61)	(26.02)	(26.72)	(12.4)
V.	Exceptional Items/Prior Period Items			9.62,630		130-72-3	45600
VI.	Profit/ (Loss) before tax (IV-V)	(9.95)	(17.69)	(24.62)	*		
/II.	Tax expense:	0.86		(14.61)	(26.02)	(26.72)	(12.4)
	(1) Current tax	7.0000	(0.50)	(2.81)	3.01	(3.04)	2.30
	(2) Deferred tax	0.65	(0.94)	1.29	1.86	5.42	10.51
	Net Profit (Loss) for the mode 4 for	0.21	0.44	(4.09)	1.15	(8.46)	(8.1)
	continuing operations (VI-VII)	(10.81)	(17.19)	(11.80)	(29.03)	(23.68)	(14.79
Х.	Profit/(loss) from discontinued operations	92	120	14	720		
ŭ.	Tax expenses of discontinued operations						-
	Profit/(loss) from Discontinued operations (after tax) (IX-X)			- 2			- 1941 - 1941
II.	Profit/(loss) for the period (VIII+XI)	(10.81)	(17.19)	(11.80)	(29.03)	199 (6)	(2.4.80
ш,	Other Comprehensive Income		(2,112)	(22,50)	(45,03)	(23.68)	(14.79
	A. (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss	*					-
	B. (i) Items that will be reclassified to profit or loss	(0.19)	0.57	-	(1.42)	(10.18)	(0.43
	(ii) Income tax relating to items that will be	(0,13)	0.67	(2.30)		100000	101.467
_	reclassified to profit or loss		51				
IV.	Total Comprehensive Income for the period (XII+XIII)Comprising Profit (Loss) and Other,comprehensive Income for the period)	(11.00)	(16.52)	(14.10)	(30.45)	(33.86)	(15.21)
	Minority Interest	0.92	0.10	0.71	2.15	5.49	0.40
VI	Total Comprehensive Income for the period after Minority Interest (XIV-XV)	(11.93)	(16.63)	(14.81)	(32.60)	(39.35)	9.40
. (Earnings per equity share (for continuing operation):					30000	
- (1) Basic	(0.14)	(0.21)	(0.15)	10.700	12430	
	2) Diluted	(0.14)	(0.21)		(0.38)	(0.36)	(0.30)
VI	Earnings per equity share (for discontinuing operation):	(0.11)	(0.21)	(0.15)	(0.38)	(0.36)	(0.30)
-	1) Basic						
	2) Diluted	-		100		-	
1		•440					
c	armings per equity share (for discontinuing & continuing operation):						
The same	1) Basic 1 Diluted	(0.14)	(0.21)	(0.15)	(0.38)	(0.36)	(0.30)

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.) 4-4-231/1/2/ABC, Inderbagh, Sultanbazar, Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370

Email: Info@trimurthidrugs.com Website: www.trimurthidrugs.com CIN No: L67120TG1994PLC018956



TRIMURTHI LIMITED SCHEDULE III OF THE COMPANIES ACT 2013 PART-II

			QUARTER ENDE	U	NINE MONTHS ENDED		YEAR ENDED	
	Particulars	31.12.2019 (UNAUDITED)	30.09.2019	31.12.2018 (UNAUDITED)	31.12.2019 (UNAUDITED)	(UNAUDITED)	(AUDITED)	
A	Particulars Of Share Holding							
	Public Share Holding			PA 50 100	29,00,600	29,00,600	29,00,600	
-	- Number of Shares	29,00,600	29,00,600	29,00,600		35.81%	35.81%	
	- Percentage of shareholding	35.81%	35.81%	35.81%	35.81%	33.01 %	33.01.1	
	Promoters and promoter group shareholding		1000					
-	a. Pledged / encumbured						_	
_	- No of Equity Shares			¥6				
	Percentage of Shares (of the shareholding of promoter and promoter group)		1.0		15	- 2	7.50	
	Percentage of Shares (of the total share capital of the company)	*		28		. 8		
_	b. Non encumbured				F1 00 100	21 00 100	51,99,400	
	- No of Equity Shares	51,99,400	51,99,400	51,99,400	51,99,400	51,99,400	31,99,400	
	 Percentage of Shares (of the shareholding of promoter and promoter group) 	100.003	100.00%	100,00%	100.00%	100.00%	100,009	
	Percentage of Shares (of the total share capita of the company)	64.193	64.19%	64.19%	64.193	64.19%	64.193	

	Particulars	3 Months Ended (31/12/2019)
B.	Investor Complaints	
-	Pending at the beginning of the quarter	-NIL-
\vdash	Received during the quarter	-NIL-
Н	Disposed during the quarter	-NIL-
\vdash	Remaining unsolved during the quarter	-NIL-

Segment Reporting

		QUARTER ENDE	AKTER ENDED		THS ENDED	YEAR ENDED
Particulars	31.12.2019 (UNAUDITED)	30.09,2019 (UNAUDITED)	31.12.2018 (UNAUDITED)	31.12.2019 (UNAUDITED)	31.12.2018 (UNAUDITED)	31.03.2018 (AUDITED)
Segment Revenue					400.00	61171
a. Pharma Business	124.46	148.96	151.10	404,32	480.88	544.64 76.96
b. Financial Services	13.08	7,39	14.13	33.35	44.94	/6.96
c. Investments	1.23	(0.07)	(0.23)	5.01	1.85	900.74
d. Foods	109.46	111.09	81.11	301.71	244.82	259.71
e. Trading in Shares	18.41	15.08	3.56	52.62	20,83	189.63
Total	266.64	282.44	249.67	797.01	793.33	1,070.94
Less: Inter Segment Revenue	1911		i with	*		-
Net Sales/ Income From Operations	266.64	282.44	249.67	797.01	793.33	1,070.94
2. Segment Profits (Before tax & Interest Fro	m Each Segment)					
a. Pharma Business	2.19	0.39	2.32	- 6.53	18.19	16.91
b. Financial Services	13.08	14.09	8.92	33.35	27.07	54.40
c Investments	1.23	(0.07)	(0.23)	5.01	1.85	0.92
d. Foods	(13.20)	(6.12)	(28.06)	(25.43)		(68.40
e. Trading in Shares	(13.25	(25.97)	2.44	(45.48)	9.16	(8.58)
Total	(9.95	(17.69)	(14.61)	(26.02)	(26.72)	(4.75
Less						
i. Interest	-	+		*	-	16.01
ii. Other Un-allocable expenses net off		-		- 8		1(3
iii. Un-allocable Income			- +			meta:
Total Profit Before Tax	(9.95	(17.69)	(14.61)	(26.02	(26.72)	(20.76
3. Capital Employed			200	1	I a serven	B
a. Pharma Business	74.99	84.70	84.98	74.99	84.98	98.29
b. Financial Services	369.90		450.93	369.90	450.93	521.58
c. Investments	30.19		39.39	30.19	39.39	63.21
d Foods	123.41	-01763	189.71	123.41	189.71	219.43
e Trading in Shares	460.97		312.03	460.97	312.03	360.92
It is a state of the state of t	1,059.46	THE RESERVE OF THE PERSON NAMED IN COLUMN TWO IS NOT THE PERSON NAMED IN COLUMN TWO IS NAMED IN COLUMN TW	1,077.03	1,059,46	1,077.03	1,263.41

TRIMURTHI LIMITED

|Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.) 4-4-231/1/2/ABC, Inderbagh, Sultanbazor, Hyderabad - 500 095, T.S. INDIA, | Tel; 040 24757370 Email: Info@trimurthidrugs.com

Website: www.trimurthidrugs.com CIN No: L67120TG1994PLC018956






Notes:

- 1 Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.
- 2 The financial results were reviewed by the Audit Committee and then approved at the meeting of the Board of Directors of the Company beld on 10-02-2020
- 3 The Consolidated Unaudited Financial Results have been prepared and subjected to Limited Review by the Statutory Auditors in accordance with Indian Accounting Standards (Ind-AS) as notified by Ministry of Corporate Affairs; Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III Division II of Companies Act, 2013. The Limited Review was carried out by Statutory Auditors for the Quarter ended 31st December 2019. The Ind AS Complaint figures for the Corresponding previous Quarter ended 30th September 2019 have not been subject to review or audit, however the Company's management has exercised necessary due deligence to ensure that such financial results provide a true and fair view of its affairs.
- The results are also available on the webiste of the Company

Place: Hyderabad Date: 10-02-2020



Email: info@trimurthidrugs.com Website: www.trimurthidrugs.com CIN No: L67120TG1994PLC018956



: (91-40) 2332 6666, 2331 2554

2339 3967, 2332 1470

Fax

: (91-40) 2339 2474 : pmurali.co@gmail.com E-mail

info@pmurali.com

Website: www.pmurali.com

Limited Review Report - Consolidated Financial Results

The Board of Directors, Trimurthi Limited, Hyderabad.

Limited Review Report on unaudited consolidated financial results for the Quarter and Nine month ended 31th December 2019

- We have reviewed the accompanying statement of unaudited consolidated financial results ("the statement") of Trimurthi Limited Group comprising Trimurthi Limited ("the Parent") and its subsidiaries (together referred to as 'the Group'), for the quarter ended 31th December 2019 and year to date results for the period 1stApril 2019 to 31th December 2019 ("the Statement")attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including relevant circulars issued by SEBI from time to time.
- The preparation of "the Statement" in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company in their meeting held on 10th February 2020. Our responsibility is to express a conclusion on "the Statement" based on our review.
- We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the Securities and Exchange board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015as amended, to the extent applicable



P. MURALI & CO.,

CHARTERED ACCOUNTANTS 6-3-655/2/3, SOMAJIGUDA, HYDERABAD - 500 082. INDIA

: (91-40) 2332 6666, 2331 2554 Tel.

2339 3967, 2332 1470

: (91-40) 2339 2474 Fax E-mail: pmurali.co@gmail.com

info@pmurali.com

Website: www.pmurali.com

The consolidated unaudited results include the results of the following entities:

- (a) Trimurthi Foods Limited (wholly owned subsidiary)
- (b) Trimurthi Pharmaceuticals India Private Limited (subsidiary)

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali& Co. Chartered Accountants

FRN: 0072575

Partner M.No. 024784

UDIN: 20024784AAAABY6448

Place: Hyderabad Date: 10-02-2020